I would think that with the 10m in the kitty that they will now be able to push through at a more rapid pace those projects that were previously progressing slowly due to financial constraints...
It will be a make or break year IMO....they have spent the last 12 months or so building the contacts and partnerships and completing some clinical trials...The funding will hopefully turbo boost them into the next phase...It would appear that the company has not quite hit the target yet...the target being commercial products that would add significant value to the company..
One of the major strategies is to ."Mature product focus into Preclinical development phase"
Correct me if I am wrong but from the recent announcement it would appear that this is where the value added occurs. All companies at this stage of development quoted in the Announcement page 22 of the 2015 investment presentation had a market cap of $380m.
"Pre-GFC…Preclinical*M&A*exits*for*platforms*were*hot!*
! Median M&A value=380m or 38 cents per share for PYC
! All companies with the exception of CAT,CovX and Adnexus were at pre clinical stage of development at the &me of acquisition)
(20min delay)